Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587184 | 0.93 | ESR2 (0.62) | ESR2NR1H2USP30NPC1RAB9A | |
| SCHEMBL29676899 | 0.93 | ESR2 (0.62) | ESR2NR1H2USP30NPC1RAB9A | |
| SCHEMBL2515678 | 0.93 | NR1H2 (0.61) | ESR2NR1H2USP30NPC1RAB9A | |
| SCHEMBL29964782 | 0.93 | NR1H2 (0.61) | ESR2NR1H2USP30NPC1RAB9A | |
| SCHEMBL19638994 | 0.87 | ESR2 (0.52) | ESR2NR1H2USP30NPC1RAB9A | |
| SCHEMBL3429990 | 0.86 | ESR2 (0.54) | ESR2NR1H2NPC1RAB9APRMT5 | |
| SCHEMBL2589826 | 0.86 | ROCK1 (0.48) | ESR2NR1H2USP30PRMT5WDR77 | |
| SCHEMBL594429 | 0.83 | CHRM4 (0.45) | ESR2NR1H2USP30PRMT5WDR77 | |
| SCHEMBL868675 | 0.83 | USP30 (0.43) | ESR2USP30PRMT5WDR77BACE1 | |
| SCHEMBL31167558 | 0.83 | USP30 (0.43) | ESR2USP30PRMT5WDR77BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| EP-2937344-B1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| EP-2937344-B1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9447074-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-7696193-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | ESR2 573/4885NR1H2 107/4885USP30 3084/4885 |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | ESR2 2390/4885NR1H2 637/4885USP30 1042/4885 |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | ESR2 2390/4885NR1H2 637/4885USP30 1042/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | ESR2 1181/4885NR1H2 665/4885USP30 2922/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | ESR2 2190/4885NR1H2 963/4885USP30 3343/4885 |
| US-20160355505-A1 | NOVEL COMPOUNDS | SYK, NFATC1, BTK | ESR2 3007/4885NR1H2 1423/4885USP30 4043/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | ESR2 2016/4885NR1H2 863/4885USP30 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.